Viromed to announce Phase I study results of VM202
Published: 2008-10-28 06:40:00
Updated: 2008-10-28 06:40:00
Viromed Co., Ltd. plans to present the phase I study results of VM202 (DNA-based medicine for ischemic disease including peripheral and coronary artery disease) in a forthcoming society in Seoul next month and in the United Stated next March.
In Korea, the phase I, dose-escalation study has co...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
